Atorvastatin

HMG-CoA reductase inhibitors (statins)

ATC code: C10AA05 (Atorvastatin)

Brand names

Lipitor, Atorvaliq

Mechanism of action

Reversible competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme of hepatic cholesterol synthesis. Depletes intracellular cholesterol, upregulates LDL receptors on hepatocytes, and increases LDL clearance from plasma. Lowers LDL by 35–55 % depending on dose, triglycerides by 15–30 %, with a small rise in HDL.

Indications

Dyslipidemia, primary CV prevention

First line

In adults without established CVD, statin therapy is guided by risk stratification. USPSTF 2022 recommends statins in adults 40–75 with at least one CV risk factor and a 10-year ASCVD risk of 10 % or more. ESC/EAS 2019 uses SCORE2 and titrates aggressiveness by risk category.

Sources

Established ASCVD, secondary prevention

First line

High-intensity statins (atorvastatin 40–80 mg daily) are the foundation of secondary prevention after ACS, MI, ischemic stroke, TIA, revascularization, or in established atherosclerotic vascular disease. Target per ESC/EAS 2019 is a ≥ 50 % LDL reduction from baseline and LDL below 1.4 mmol/L. Cholesterol Treatment Trialists meta-analyses show a 20 % reduction in major vascular events per 1 mmol/L LDL lowering.

Sources

Familial hypercholesterolemia

First line

Heterozygous FH requires high-intensity statins started early (from age 8–10 per pediatric ESC/EAS consensus). LDL target is below 2.5 mmol/L in adults without additional risk factors and below 1.8 mmol/L with them. Ezetimibe and, if needed, PCSK9 inhibitors are added when targets are not met.

Sources

Vessel cleansing (marketed indication)

Not recommended

'Vessel cleansing' is not a concept used in international clinical guidelines. Statins are prescribed based on cardiovascular risk stratification, not for 'cleansing'. The idea of mechanically 'removing plaques' with a drug contradicts pharmacokinetics. The evidence-based benefit of statins is reduced cardiovascular mortality via plaque stabilization and LDL reduction, not 'dissolution'.

Sources

ESC/EAS: 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias (2019)

Practical notes

Timing and administration

Atorvastatin may be taken at any time of day with or without food. Unlike simvastatin and lovastatin, atorvastatin has a long half-life (14 h for the parent drug and up to 30 h for active metabolites), so evening dosing has no clinical advantage over morning dosing. Choose the time the patient is least likely to miss.

Monitoring

Baseline: lipid profile, ALT, AST, and CK when clinically indicated. Follow-up lipid profile 4–12 weeks after initiation and any dose change, then every 6–12 months on stable therapy. Routine ALT/AST monitoring without symptoms is not required per ACC/AHA 2018. CK is measured only when muscle symptoms appear. Statin-associated myopathy is confirmed at CK above 4× ULN.

Special situations

Grapefruit and grapefruit juice in large amounts (over 1 L/day) increase atorvastatin exposure. Moderate intake is clinically insignificant. Caution with concurrent macrolides (clarithromycin, erythromycin), azole antifungals, cyclosporine, gemfibrozil, amiodarone — dose reduction or temporary hold may be required. During acute febrile illnesses with myalgia, distinguishing statin myalgia from viral myalgia can be difficult.

Common myths

Myth: 'statins destroy the liver'. Fact: clinically significant transaminase elevation occurs in less than 1 % of patients and is usually transient. Routine liver enzyme monitoring in asymptomatic patients is not required. Myth: 'statins should be taken in courses'. Fact: statins are long-term (usually lifelong) therapy. Discontinuation rapidly returns LDL to baseline and raises cardiovascular risk. Myth: 'statins cause diabetes'. Fact: a small excess risk exists (roughly 1 case of T2D per 250 patients over 4 years), but the benefit from reduced cardiovascular events clearly outweighs it in patients with an indication.

Safety

Contraindications

Active liver disease or unexplained persistent transaminase elevation
Pregnancy and planned pregnancy
Breastfeeding
Hypersensitivity to any component

Serious adverse effects

Rhabdomyolysis (rare, under 0.1 %, with CK above 10× ULN, myoglobinuria, AKI)
Immune-mediated necrotizing myopathy (very rare)
Drug-induced liver injury (rare)

Common adverse effects

Myalgia without CK elevation
Headache
Dyspepsia, nausea
Arthralgia
Transient transaminase elevation (usually below 3× ULN)

Uncommon adverse effects

Rash, urticaria
Sleep disturbance
Peripheral neuropathy

PregnancyFDA X

FDA category X. Cholesterol and its derivatives are required for normal fetal development, and suppressing cholesterol synthesis in the first trimester is associated with potential teratogenic risk. Statins are stopped 3 months before a planned pregnancy. An unplanned pregnancy requires immediate discontinuation.

Breastfeeding

Contraindicated during breastfeeding. If therapy is required, breastfeeding is discontinued.